Visit KACTUS at BIO KOREA 2024 in Seoul!

By Mallory Griffin

Booth #D30

Next week, KACTUS is thrilled to participate in BioKorea in Seoul. This event, a significant gathering for biotechnology innovation and global collaboration, offers an ideal platform for showcasing advanced recombinant protein and enzyme solutions. At KACTUS, our goal for the meeting is to engage with industry leaders and researchers, demonstrate our innovative recombinant protein solutions, and foster collaborations that drive forward the potential of drug development. The BioKorea Annual Meeting serves as a pivotal forum for sharing research, advancing knowledge, and networking with experts across the field.

Featured Products

MHC Monomers & Tetramers

AAV Titration ELISA Kits

AccuBase Cytosine Base Editor

VLP-Displayed Antigens


mRNA Enzymes

Why attend the BIO Korea Annual Meeting? 

BioKorea 2024 is a premier gathering for biotechnology and healthcare innovations, featuring experts and world-class scholars from the biohealth industry. The event also boasts an extensive exhibit hall, enhancing opportunities for discovery and professional networking in the biosciences sector. Register now to fully engage with the educational and collaborative opportunities available at BioKorea! 

Event Details: 

What: BIO KOREA 2024

When: May 8-10, 2024

Where: COEX, Seoul


KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our expansive catalog, boasting over 3000 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of our product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.